A Fulminant Hepatic Failure Model in the Rat
暂无分享,去创建一个
Mehmet Toner | Ronald G. Tompkins | Martin L. Yarmush | Ulysses J. Balis | R. Tompkins | M. Toner | M. Yarmush | U. Balis | Masaya Shito | M. Shito
[1] S. Sabesin,et al. D-Galactosamine Hepatitis I. Hepatocellular Injury and Fatty Liver Following A Single Dose , 1971 .
[2] D. Keppler,et al. Galactosamine induced liver injury. , 1972, Progress in liver diseases.
[3] T. Chang,et al. Biochemical, hematological and histological changes in a fulminant hepatic failure rat model for artificial liver assessment. , 1979, Artificial organs.
[4] D. Samuel,et al. Orthotopic Liver Transplantation in Fulminant and Subfulminant Hepatitis The Paul Brousse Experience , 1995, Annals of surgery.
[5] L. Flendrig,et al. Semipermeable hollow fiber membranes in hepatocyte bioreactors: a prerequisite for a successful bioartificial liver? , 2008, Artificial organs.
[6] R. Strieter,et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. , 1989, Science.
[7] J. Ljubimova,et al. Fulminant hepatic failure in rats: Survival and effect on blood chemistry and liver regeneration , 1996, Hepatology.
[8] J. Fierer,et al. D-Galactosamine hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice. , 1985, Gastroenterology.
[9] Regional cerebral edema and chloride space in galactosamine‐induced liver failure in rats , 1997, Hepatology.
[10] M B Furie,et al. Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha. , 1989, Journal of immunology.
[11] F. Cerra,et al. Gel-entrapment bioartificial liver therapy in galactosamine hepatitis. , 1995, The Journal of surgical research.
[12] A. Morelli,et al. Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice. , 1996, Gastroenterology.
[13] Y. Shiratori,et al. Modulation of hepatotoxicity by macrophages in the liver , 1988, Hepatology.
[14] F. Cerra,et al. An anesthetized model of lethal canine galactosamine fulminant hepatic failure , 1995, Hepatology.
[15] L. Blendis,et al. Reversal of experimental acute hepatic failure in the rat. , 1980, The Journal of surgical research.
[16] C. Dinarello,et al. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. , 1991, The Journal of clinical investigation.
[17] T. Chang,et al. Brain edema and the blood brain barrier in galactosamine-induced fulminant hepatic failure rats. An animal model for evaluation of liver support systems. , 1990, ASAIO transactions.
[18] M. Leist,et al. Tumor necrosis factor-induced hepatic DNA fragmentation as an early marker of T cell-dependent liver injury in mice. , 1995, Gastroenterology.
[19] D. Samuel,et al. Liver transplantation in fulminant and subfulminant hepatitis , 1989 .
[20] S. Seki,et al. Effects of putrescine on D‐galactosamine–induced acute liver failure in rats , 1990, Hepatology.
[21] T. Yoshida,et al. Endotoxin‐induced cytokine gene expression and excretion in the liver , 1994, Hepatology.
[22] J. Terblanche,et al. Animal models of fulminant hepatic failure , 1991, Digestive diseases and sciences.
[23] M. Kitajima,et al. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. , 1997, Transplantation.
[24] D. V. van Thiel,et al. A dog model for acetaminophen-induced fulminant hepatic failure. , 1989, Gastroenterology.
[25] A. Demetriou,et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. , 1997, Annals of surgery.
[26] M. Leist,et al. Interleukin‐1 and nitric oxide protect against tumor necrosis factor α‐induced liver injury through distinct pathways , 1995, Hepatology.
[27] Y. Shiratori,et al. Role of polymorphonuclear leukocytes in galactosamine hepatitis: Mechanism of adherence to hepatic endothelial cells , 1994, Hepatology.
[28] J. D. Albert,et al. Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.
[29] K. Maezono,et al. Effect of alanine on D‐galactosamine‐induced acute liver failure in rats , 1996, Hepatology.
[30] K. Soo,et al. An improved model of galactosamine-induced fulminant hepatic failure in the pig. , 1999, The Journal of surgical research.
[31] C. Lowenstein,et al. Impaired liver regeneration in inducible nitric oxide synthasedeficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.